Which F1 Teams Use Honda Engines?Stock market today: Wall Street inches higher to set more records

Shop smart! Here are all the best products Yahoo editors tested in 2024Rookie quarterback Michael Penix Jr. showed the poise in his first NFL start the Falcons will need to take advantage of their opportunity to end a six-year playoff drought. Powered by a big-play defense that produced two pick-6s, a solid starting debut by Penix and two rushing touchdowns by Bijan Robinson, the Falcons cruised past the hapless New York Giants 34-7 on Sunday. On Sunday night, the Falcons (8-7) received the assist they needed when Tampa Bay lost at Dallas . Because the Falcons swept the Buccaneers, they hold the tiebreaker advantage if they remain tied atop the division. The Falcons have games remaining at Washington on Sunday night and at home against Carolina to close the regular season. If Atlanta wins both games, it would win the division and have a home playoff game. The Falcons are assured of their best record since a 10-6 finish under coach Dan Quinn in 2017, their most recent playoff season. Quinn is in his first season as Washington's coach and has led the Commanders (10-5) to three straight wins, including Sunday's 36-33 victory over Philadelphia. Penix, the No. 8 overall pick in this year's NFL draft, was promoted after coach Raheem Morris benched Kirk Cousins. Penix completed 18 of 27 passes for 202 yards with one interception on a pass that should have been caught by tight end Kyle Pitts. Penix is not a dual-threat quarterback, but he showed the ability to escape pressure in the pocket that Cousins lacks following his 2023 Achilles tendon injury. The left-hander's superior arm strength also was immediately obvious. Robinson's production provided a safety net for the offense which helped make for a smooth transition to Penix. Robinson had scoring runs of 2 and 4 yards. Robinson has rushed for 10 touchdowns this season. He's the first Atlanta player with 10 more more rushing touchdowns since Devonta Freeman during the 2016 Super Bowl season. Robinson ran for 94 yards on 22 carries and had 103 yards from scrimmage. His 11th game this season with at least 100 yards from scrimmage are the most for the Falcons since Warrick Dunn's 11 in 2005. Morris said Robinson deserves to be considered with Philadelphia's Saquon Barkley in discussions regarding the league's top running backs. “Bijan has been outstanding all year in the things that he’s able to do," Morris said. “He’s special. If it wasn’t for this other guy out in Philly, he’d get a lot more recognition across the league. But that guy is having a special year, and Bijan’s not far behind him.” With kicker Younghoe Koo on injured reserve and watching from the sideline, Riley Patterson was wide left on his first field-goal attempt from 43 yards. Patterson rebounded to make attempts from 52 and 37 yards. Jessie Bates III and Matthew Judon each had a pick-6 to highlight a day of big plays for the defense. Arnold Ebiketie had his fifth sack of the season and added a fumble recovery. Kaden Ellis added a strip-sack. He also has five sacks this season, including sacks in four consecutive games. It is the longest streak for Atlanta since Patrick Kerney had sacks in five straight games in 2001. There was some thought that a change at quarterback could be good news for Pitts, who often seemed to be missing in action with Cousins running the offense. After all, a tight end often is a natural target for quick passes from a rookie making his first start. Instead, Pitts had a poor start to the Penix era when he bobbled his first pass from the left-hander, creating an interception by cornerback Cor’Dale Flott. Pitts caught a 7-yard pass on his only other target. For the season, Pitts has 41 catches for 543 yards and three touchdowns. There will be much interest in this week's injury report after WR Drake London (hamstring) was hurt in the second half. Morris provided an optimistic postgame outlook on London. CB Antonio Hamilton (quad) did not return after leaving the game in the first half. 8: Bates has four interceptions and four forced fumbles. His combined eight forced turnovers lead the NFL. The game against Jayden Daniels and the Commanders is a reminder Penix was only the fourth of six quarterbacks selected in the first round of the NFL draft. Daniels, from LSU, was the No. 2 overall pick behind Caleb Williams by Chicago. AP NFL: https://apnews.com/hub/nflIn a filing made public Tuesday, Trump’s lawyers told Manhattan Judge Juan M. Merchan that dismissal is warranted because of the “overwhelming national mandate granted to him by the American people on November 5, 2024.” They also cited President Joe Biden’s recent pardon of his son, Hunter Biden, who was convicted of tax and gun charges . “President Biden asserted that his son was ‘selectively, and unfairly, prosecuted,’ and ‘treated differently,’" Trump’s legal team wrote. The Manhattan district attorney, they claimed, engaged in the type of political theater "that President Biden condemned.” Prosecutors will have until Dec. 9 to respond. They have said they will fight any efforts to dismiss the case but indicated a willingness to delay the sentencing until after Trump’s second term ends in 2029. In their filing Monday, Trump's attorneys dismissed the idea of holding off sentencing until Trump is out of office as a “ridiculous suggestion.” Following Trump’s election victory last month, Merchan halted proceedings and indefinitely postponed his sentencing, previously scheduled for late November, to allow the defense and prosecution to weigh in on the future of the case. He also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. Trump has been fighting for months to reverse his conviction on 34 counts of falsifying business records to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier. He says they did not and denies wrongdoing. Taking a swipe at Bragg and New York City, as Trump often did throughout the trial, the filing argues that dismissal would also benefit the public by giving him and “the numerous prosecutors assigned to this case a renewed opportunity to put an end to deteriorating conditions in the City and to protect its residents from violent crime.” Clearing Trump, the lawyers added, also would allow him to “to devote all of his energy to protecting the Nation.” The defense filing was signed by Trump lawyers Todd Blanche and Emil Bove, who represented Trump during the trial and since were selected by the president-elect to fill senior roles at the Justice Department. A dismissal would erase Trump’s historic conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office. Trump takes office Jan. 20. Merchan hasn’t set a timetable for a decision. Merchan could also decide to uphold the verdict and proceed to sentencing, delay the case until Trump leaves office, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court or choose some other option. Prosecutors cast the payout as part of a Trump-driven effort to keep voters from hearing salacious stories about him. Trump’s then-lawyer Michael Cohen paid Daniels. Trump later reimbursed him, and Trump’s company logged the reimbursements as legal expenses — concealing what they really were, prosecutors alleged. Trump pledged to appeal the verdict if the case is not dismissed. He and his lawyers said the payments to Cohen were properly categorized as legal expenses for legal work. A month after the verdict, the Supreme Court ruled that ex-presidents can’t be prosecuted for official acts — things they did in the course of running the country — and that prosecutors can’t cite those actions to bolster a case centered on purely personal, unofficial conduct. Trump’s lawyers cited the ruling to argue that the hush money jury got some improper evidence, such as Trump’s presidential financial disclosure form, testimony from some White House aides and social media posts made during his first term. Prosecutors disagreed and said the evidence in question was only “a sliver” of their case. If the verdict stands and the case proceeds to sentencing, Trump’s punishments would range from a fine to probation to up to four years in prison — but it’s unlikely he’d spend any time behind bars for a first-time conviction involving charges in the lowest tier of felonies. Because it is a state case, Trump would not be able to pardon himself once he returns to office. Presidential pardons apply only to federal crimes.

S. Dakota St. 75, Missouri St. 55Eton Pharmaceuticals stock soars to all-time high of $11.12WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree” or "the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis [email protected] Consolidated Balance Sheets (in thousands, except share and per share data) Consolidated Statements of Operations (in thousands, except per share data)CLEVELAND (AP) — Shortly after doing a face-down snow angel, firing a few celebratory snowballs and singing “Jingle Bells” on his way to the media room, Jameis Winston ended his postgame news conference with a simple question. “Am I a Brown yet?” he asked. He is now. And who knows? Maybe for a lot longer than expected. Winston entered Cleveland football folklore on Thursday night by leading the Browns to a 24-19 win over the division rival Pittsburgh Steelers, who had their five-game winning streak stopped. Winston's performance at Huntington Bank Field, which transformed into the world's largest snow globe, not only made him an instantaneous hero in the eyes of Browns fans but added another wrinkle to the team's ever-changing, never-ending quarterback conundrum. In his fourth start since Deshaun Watson's season-ending Achilles tendon injury, Winston made enough big plays to help the Browns (3-8) get a victory that should quiet conjecture about coach Kevin Stefanski's job. Some wins mean more than others. In Cleveland, beating the Steelers is as big as it gets. But beyond any instant gratification, Winston has given the Browns more to consider as they move forward. Watson's future with Cleveland is highly uncertain since it will still be months before the team has a grip on whether he's even an option in 2025, his fourth year since signing a $230 million, fully guaranteed contract that has proven calamitous. It's also possible the Browns will cut ties with Watson. They signed Winston to a one-year contract to be Watson's backup. But the unexpected events of 2024 have changed plans and led to the possibility that the 30-year-old Winston could become Cleveland's full-time QB or a bridge to their next young one. So much is unclear. What's not is that Winston, who leaped into the end zone on fourth-and-2 for a TD to put the Browns ahead 18-6 in the fourth quarter, is a difference maker. With his larger-than-life personality and the joy he shows whether practicing or throwing three touchdown passes, he has lifted the Browns. A man of faith, he's made his teammates believe. Winston has done what Watson couldn't: made the Browns better. “A very, very authentic person,” Stefanski said Friday on a Zoom call. “He’s the same guy every single day. He's the same guy at 5 a.m. as he at 5 p.m. He brings great energy to everything he does, and I think his teammates appreciate that about him.” Winston, who is 2-2 as a starter with wins over the Steelers and Baltimore Ravens, has a knack for inspiring through fiery, preacher-like pregame speeches. But what has impressed the Browns is his ability to stay calm in the storm. “He doesn’t get rattled,” said Myles Garrett, who had three sacks against the Steelers . “He’s just tuned in and focused as anyone I’ve seen at that position. Turn the page. There was a turnover, came back to the sideline, ‘Love you. I’m sorry. We’re going to get it back.’ He was already on to the next one, ‘How can we complete the mission?’ “I have a lot of respect for him. First was from afar and now seeing it on the field in front of me, it’s a blessing to have someone who plays a game with such a passion and want-to. You can’t ask for a better teammate when they take those things to heart and they want to play for you like we’re actually brothers and that’s what we have to attain. That brotherhood.” Winston has done something else Watson couldn't: move the offense. The Browns scored more than 20 points for just the second time this season, and like Joe Flacco a year ago, Winston has shown that Stefanski's system works with a quarterback patient enough to let plays develop and unafraid to take shots downfield. The conditions certainly were a factor, but the Browns were a miserable 1 of 10 on third down, a season-long trend. However, Cleveland converted all four fourth-down tries, including a fourth-and-3 pass from Winston to Jerry Jeudy with 2:36 left that helped set up Nick Chubb's go-ahead TD run. RT Jack Conklin. Garrett outplayed Steelers star T.J. Watt in their rivalry within the rivalry partly because Conklin did a nice job containing Pittsburgh's edge rusher, who was held without a sack and had one tackle for loss. Conklin has made a remarkable comeback since undergoing reconstructive knee surgery last year. Owners Dee and Jimmy Haslam. Their desire to build a dome is well intended, but an indoor game could never come close to matching the surreal setting of Thursday night, when snow swirled throughout the stadium and covered nearly all the yard lines and hash marks. “It was beautiful,” Winston said. WR Cedric Tillman is in the concussion protocol. He had two catches before taking a big hit on the final play of the third quarter. 9 — Consecutive home wins for the Browns in Thursday night games. Three of those have come against Pittsburgh. An extended break before visiting the Denver Broncos on Dec. 2. AP NFL: https://apnews.com/hub/NFL

None